The invention relates to the use of an iron-score based on the expression level of at least 1 gene, in particular at least 3, preferably at least 5, and even preferably 8 genes selected in the group consisting of APEX1, TFRC, HIF1A, ABCG2, SCARA3, IREB2, SFXN4 and SLC39A14 involved in the iron metabolism, as a prognosis marker in subjects having MCL, in particular for identifying subjects with a poor outcome such as a relapse and/or death.

Methods of treating cancer with a combination of a WEE1 inhibitor and a DNA-damaging agent in patients having SLFN11-deficient cancer cells are disclosed herein.

Methods of treating cancer with a combination of a WEE1 inhibitor and a DNA-damaging agent in patients having SLFN11-deficient cancer cells are disclosed herein.

There is provided a skin-care balm comprising 15% to 45% (w/w) of two or more waxes, wherein a first wax has a melting point of 70° C. to 90° C. and a second wax has a melting point of 30° C. to 60° C., the balm further comprising 45% to 70% (w/w) of an emollient and a skin soothing agent. The skin-care balm can be applied to the skin in the perinasal area. There is also provided a combination product comprising a skin-care balm and a nasal spray product.

There is provided a skin-care balm comprising 15% to 45% (w/w) of two or more waxes, wherein a first wax has a melting point of 70° C. to 90° C. and a second wax has a melting point of 30° C. to 60° C., the balm further comprising 45% to 70% (w/w) of an emollient and a skin soothing agent. The skin-care balm can be applied to the skin in the perinasal area. There is also provided a combination product comprising a skin-care balm and a nasal spray product.

A combination product comprising a dispensing head (10, 10′) mounted on a top of a container (20, 20′) containing a formulation for nasal administration, and a solidified skin-care balm (50) for application around the nose contained in a balm holder element (30, 30″) located on a bottom (24) of the container (20).

A combination product comprising a dispensing head (10, 10′) mounted on a top of a container (20, 20′) containing a formulation for nasal administration, and a solidified skin-care balm (50) for application around the nose contained in a balm holder element (30, 30″) located on a bottom (24) of the container (20).

The present invention relates to a pharmaceutical or veterinary composition for its use in preventing and/or treating a MERS-CoV (Middle-East Respiratory Syndrome) coronavirus infection, characterised in that it comprises, in a suitable pharmaceutical vehicle, at least one compound chosen from apigenin and berberine.

The present invention relates to a pharmaceutical or veterinary composition for its use in preventing and/or treating a MERS-CoV (Middle-East Respiratory Syndrome) coronavirus infection, characterised in that it comprises, in a suitable pharmaceutical vehicle, at least one compound chosen from apigenin and berberine.

In one aspect, the present disclosure provides analogs of thailanstatin of the formula wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein. ##STR00001##